Actively Recruiting

Age: 18Years +
All Genders
NCT04612075

The EMINENCE Study - PET/MR Imaging of Head Neck Cancer

Led by Norwegian University of Science and Technology · Updated on 2026-04-14

390

Participants Needed

2

Research Sites

411 weeks

Total Duration

On this page

Sponsors

N

Norwegian University of Science and Technology

Lead Sponsor

S

St. Olavs Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

Head and neck cancers (HNC) often receive radiotherapy as part of their treatment. However, unacceptable failure rates and severe side effects remain a challenge. The improvements in radiotherapy are closely related to improvements in medical imaging. Functional imaging, where intratumoural characteristics such as tumour oxygenation, metabolism, and blood vessel function can be quantified, offers possibilities to personalize the radiotherapy. In this study we will establish the clinical workflow for PET- and MRI-based radiotherapy in HNC by acquiring images prior to and during radiotherapy to develop new concepts for image-based biologically adaptive radiotherapy, both based on photon-based radiotherapy and also proton therapy, which soon will be available for cancer patients in Norway. The investigators aim to contribute towards further developments of personalised high-precision radiotherapy for HNC patients resulting in improved outcome, reduced side-effects and better quality of life.

CONDITIONS

Official Title

The EMINENCE Study - PET/MR Imaging of Head Neck Cancer

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Willing and able to give full written consent according to approved protocol
  • Histologically confirmed squamous cell carcinoma in the head and neck region (pharynx, larynx, oral cavity or sinonasal area)
  • Locally advanced disease without signs of spread (T3/T4 and/or N1-3, M0) on diagnostic imaging
  • Scheduled for definitive radiotherapy with curative intent, with or without chemotherapy
  • Adequate kidney function with creatinine clearance at least 60 ml/minute
  • Lymph node metastasis from unknown primary cancer in upper neck (level II-III) with negative PET/CT outside head-neck region may be included at investigator discretion
Not Eligible

You will not qualify if you...

  • General contraindications for MRI such as pacemaker, aneurysm clips, metal in the body, or severe claustrophobia
  • Serious other illnesses, including prior or other cancers, that may interfere with study completion or evaluation (e.g. poorly controlled diabetes)
  • Histologically confirmed squamous cell carcinoma of the same or other origin within the last five years
  • Patient chooses to withdraw from the study at any time

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

University Hospital of North Norway

Tromsø, Norway

Not Yet Recruiting

2

St Olavs Hospital, Department of Oncology

Trondheim, Norway

Actively Recruiting

Loading map...

Research Team

M

Miriam Alsaker, phd

CONTACT

K

Kathrine Røe Redalen, phd

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

The EMINENCE Study - PET/MR Imaging of Head Neck Cancer | DecenTrialz